Adamas Pharmaceuticals, Inc.
1900 Powell Street
About Adamas Pharmaceuticals, Inc.
200 articles about Adamas Pharmaceuticals, Inc.
Forest Laboratories, Inc. And Adamas Pharmaceuticals Announce Forest’s Submission Of New Drug Application For Memantine Extended Release And Donepezil Fixed-Dose Combination For Alzheimer’s Disease
Forest Laboratories, Inc. Files Lawsuit Against Several Companies For Infringement Of NAMENDA XR ® Patents
Adamas Pharmaceuticals Bags $40 Million From Forest Laboratories, Inc. For Alzheimer's Drug NDA Filing
Adamas Pharmaceuticals Presents Positive Clinical Data for ADS-5102, A Treatment for Levodopa-Induced Dyskinesia, at the World Parkinson's Congress
Adamas Pharmaceuticals Presents Positive Phase 2/3 Results for ADS-5102 for the Treatment of Levodopa-Induced Dyskinesia (LID) in Parkinson's Disease
Adamas Pharmaceuticals to Report Positive Phase 2/3 Results For ADS-5102 for the Treatment of Levodopa-Induced Dyskinesia in Parkinson's Disease
Adamas Pharmaceuticals Announces Issuance of First U.S. Patent for Nurelin™ (Amantadine HCl Extended Release) Program
Adamas Pharmaceuticals Presents New Traumatic Brain Injury Data From Its Nurelin™ Program at American Academy of Neurology Conference
Adamas Pharmaceuticals Presents Update On Nurelin(TM) Program at Cambridge Healthtech Institute's Parkinson's Conference
Adamas Pharmaceuticals' Triple Combination Antiviral Drug (TCAD) Therapy is Well Tolerated in a Pilot Study of Immunocompromised Patients With Influenza A
Adamas Pharmaceuticals Announces In Vitro Data Demonstrating TCAD Therapy is More Potent Than Double Combinations or Monotherapy Against Drug-Resistant Flu Strains
Adamas Pharmaceuticals Selects Veeva Systems, Inc.'s CRM to Support New Product Commercialization and Anticipated Growth
In Vitro Study of Adamas Pharmaceuticals' Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses
Adamas Pharmaceuticals to Present Data on Triple Combination Antiviral Drug Therapy for Drug-Resistant Influenza at 2009 ICAAC Annual Meeting
Adamas Pharmaceuticals Expands Management Team; Names Michael D. Coffee and Amy K. Patick to Executive Positions
Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain